Literature DB >> 25323587

NRF2-driven miR-125B1 and miR-29B1 transcriptional regulation controls a novel anti-apoptotic miRNA regulatory network for AML survival.

N M Shah1, L Zaitseva2, K M Bowles3, D J MacEwan4, S A Rushworth2.   

Abstract

Transcription factor NRF2 is an important regulator of oxidative stress. It is involved in cancer progression, and has abnormal constitutive expression in acute myeloid leukaemia (AML). Posttranscriptional regulation by microRNAs (miRNAs) can affect the malignant phenotype of AML cells. In this study, we identified and characterised NRF2-regulated miRNAs in AML. An miRNA array identified miRNA expression level changes in response to NRF2 knockdown in AML cells. Further analysis of miRNAs concomitantly regulated by knockdown of the NRF2 inhibitor KEAP1 revealed the major candidate NRF2-mediated miRNAs in AML. We identified miR-125B to be upregulated and miR-29B to be downregulated by NRF2 in AML. Subsequent bioinformatic analysis identified putative NRF2 binding sites upstream of the miR-125B1 coding region and downstream of the mir-29B1 coding region. Chromatin immunoprecipitation analyses showed that NRF2 binds to these antioxidant response elements (AREs) located in the 5' untranslated regions of miR-125B and miR-29B. Finally, primary AML samples transfected with anti-miR-125B antagomiR or miR-29B mimic showed increased cell death responsiveness either alone or co-treated with standard AML chemotherapy. In summary, we find that NRF2 regulation of miR-125B and miR-29B acts to promote leukaemic cell survival, and their manipulation enhances AML responsiveness towards cytotoxic chemotherapeutics.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25323587      PMCID: PMC4356334          DOI: 10.1038/cdd.2014.152

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  42 in total

1.  MicroRNA-125b expands hematopoietic stem cells and enriches for the lymphoid-balanced and lymphoid-biased subsets.

Authors:  A G Lisa Ooi; Debashis Sahoo; Maddalena Adorno; Yulei Wang; Irving L Weissman; Christopher Y Park
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-30       Impact factor: 11.205

2.  Utility of siRNA against Keap1 as a strategy to stimulate a cancer chemopreventive phenotype.

Authors:  Tim W P Devling; Christopher D Lindsay; Lesley I McLellan; Michael McMahon; John D Hayes
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-09       Impact factor: 11.205

3.  Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.

Authors:  William Blum; Ramiro Garzon; Rebecca B Klisovic; Sebastian Schwind; Alison Walker; Susan Geyer; Shujun Liu; Violaine Havelange; Heiko Becker; Larry Schaaf; Jon Mickle; Hollie Devine; Cheryl Kefauver; Steven M Devine; Kenneth K Chan; Nyla A Heerema; Clara D Bloomfield; Michael R Grever; John C Byrd; Miguel Villalona-Calero; Carlo M Croce; Guido Marcucci
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-05       Impact factor: 11.205

4.  MicroRNA-125b promotes apoptosis by regulating the expression of Mcl-1, Bcl-w and IL-6R.

Authors:  J Gong; J-P Zhang; B Li; C Zeng; K You; M-X Chen; Y Yuan; S-M Zhuang
Journal:  Oncogene       Date:  2012-07-23       Impact factor: 9.867

5.  Enforced expression of miR-125b affects myelopoiesis by targeting multiple signaling pathways.

Authors:  Ewa Surdziel; Maciej Cabanski; Iris Dallmann; Marcin Lyszkiewicz; Andreas Krueger; Arnold Ganser; Michaela Scherr; Matthias Eder
Journal:  Blood       Date:  2011-03-02       Impact factor: 22.113

6.  MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1.

Authors:  Ramiro Garzon; Shujun Liu; Muller Fabbri; Zhongfa Liu; Catherine E A Heaphy; Elisa Callegari; Sebastian Schwind; Jiuxia Pang; Jianhua Yu; Natarajan Muthusamy; Violaine Havelange; Stefano Volinia; William Blum; Laura J Rush; Danilo Perrotti; Michael Andreeff; Clara D Bloomfield; John C Byrd; Kenneth Chan; Lai-Chu Wu; Carlo M Croce; Guido Marcucci
Journal:  Blood       Date:  2009-02-11       Impact factor: 22.113

7.  MicroRNA 29b functions in acute myeloid leukemia.

Authors:  Ramiro Garzon; Catherine E A Heaphy; Violaine Havelange; Muller Fabbri; Stefano Volinia; Twee Tsao; Nicola Zanesi; Steven M Kornblau; Guido Marcucci; George A Calin; Michael Andreeff; Carlo M Croce
Journal:  Blood       Date:  2009-10-22       Impact factor: 22.113

8.  High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors.

Authors:  Stuart A Rushworth; Kristian M Bowles; David J MacEwan
Journal:  Cancer Res       Date:  2011-01-06       Impact factor: 12.701

9.  Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias.

Authors:  Brynn T Kvinlaug; Wai-In Chan; Lars Bullinger; Mukundhan Ramaswami; Christopher Sears; Donna Foster; Stanley E Lazic; Rachel Okabe; Axel Benner; Benjamin H Lee; Inusha De Silva; Peter J M Valk; Ruud Delwel; Scott A Armstrong; Hartmut Döhner; D Gary Gilliland; Brian J P Huntly
Journal:  Cancer Res       Date:  2011-04-19       Impact factor: 12.701

10.  miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells.

Authors:  Kinya Okamoto; Kenichi Miyoshi; Yoshikazu Murawaki
Journal:  PLoS One       Date:  2013-10-17       Impact factor: 3.240

View more
  30 in total

Review 1.  Epigenetic regulation of redox signaling in diabetic retinopathy: Role of Nrf2.

Authors:  Renu A Kowluru; Manish Mishra
Journal:  Free Radic Biol Med       Date:  2016-12-22       Impact factor: 7.376

Review 2.  MicroRNAs and acute myeloid leukemia: therapeutic implications and emerging concepts.

Authors:  Jared A Wallace; Ryan M O'Connell
Journal:  Blood       Date:  2017-07-27       Impact factor: 22.113

3.  Nrf2-miR-129-3p-mTOR Axis Controls an miRNA Regulatory Network Involved in HDACi-Induced Autophagy.

Authors:  Weijian Sun; Yongdong Yi; Guojun Xia; Yaxin Zhao; Yaojun Yu; Liyi Li; Chunya Hua; Bin He; Beng Yang; Chengyang Yu; Chenmin Ye; Fuyang Tu; Canjin Chen; Xiaoying Xu; Zhiqiang Zheng; Wenqian Wang; Xian Shen
Journal:  Mol Ther       Date:  2019-02-15       Impact factor: 11.454

4.  Nrf2 overexpression increases the resistance of acute myeloid leukemia to cytarabine by inhibiting replication factor C4.

Authors:  Tianzhen Hu; Chengyun Pan; Tianzhuo Zhang; Ming Ni; Weili Wang; Siyu Zhang; Ying Chen; Jishi Wang; Qin Fang
Journal:  Cancer Gene Ther       Date:  2022-07-15       Impact factor: 5.854

5.  NRF2/miR-140 signaling confers radioprotection to human lung fibroblasts.

Authors:  Nadire Duru; Ramkishore Gernapudi; Yongshu Zhang; Yuan Yao; Pang-Kuo Lo; Benjamin Wolfson; Qun Zhou
Journal:  Cancer Lett       Date:  2015-08-20       Impact factor: 8.679

6.  Targeting the KEAP1/NRF2 pathway to manipulate the expression of oncogenic and oncosuppressive miRNAs in human leukemia.

Authors:  Kristian M Bowles; Stuart A Rushworth
Journal:  Mol Cell Oncol       Date:  2018-04-19

7.  miR-126 promotes the growth and proliferation of leukemia stem cells by targeting DNA methyltransferase 1.

Authors:  Qian Ding; Qing Wang; Yi Ren; Hongqian Zhu; Zhujun Huang
Journal:  Int J Clin Exp Pathol       Date:  2018-07-01

8.  A comprehensive in vivo screen for anti-apoptotic miRNAs indicates broad capacities for oncogenic synergy.

Authors:  Fernando Bejarano; Chih-Hsuan Chang; Kailiang Sun; Joshua W Hagen; Wu-Min Deng; Eric C Lai
Journal:  Dev Biol       Date:  2021-03-01       Impact factor: 3.148

9.  Ethyl Pyruvate Attenuates Microglial NLRP3 Inflammasome Activation via Inhibition of HMGB1/NF-κB/miR-223 Signaling.

Authors:  Melis Olcum; Kemal Ugur Tufekci; Devrim Yagmur Durur; Bora Tastan; Irem Nur Gokbayrak; Kursad Genc; Sermin Genc
Journal:  Antioxidants (Basel)       Date:  2021-05-08

Review 10.  miRNA Influences in NRF2 Pathway Interactions within Cancer Models.

Authors:  Duncan Ayers; Byron Baron; Therese Hunter
Journal:  J Nucleic Acids       Date:  2015-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.